OSELTAMIVIR PHOSPHATE (oseltamivir phosphate) by Jubilant Therapeutics is 12. Approved for acute, uncomplicated illness due to influenza a, b infection in patients 2 weeks of age and 5 more indications. First approved in 2023.
Drug data last refreshed 20h ago
12.1 Mechanism of Action Oseltamivir is an antiviral drug with activity against influenza virus [see ]. 12.3 Pharmacokinetics Absorption and Bioavailability Oseltamivir is absorbed from the gastrointestinal tract after oral administration of oseltamivir phosphate and is extensively converted…
Worked on OSELTAMIVIR PHOSPHATE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects